Synergistic Enhancement of Macrophage Anti-Tumor Activity in OSCC: Insights from Combined Photothermal Therapy and CD47 Blockade

Study Background and Research Question

Oral squamous cell carcinoma (OSCC) is among the most prevalent and challenging malignant tumors globally, responsible for roughly 90% of oral malignancies. Despite the use of established interventions—surgery, radiotherapy, and chemotherapy—five-year survival rates remain modest at 50–64%, with high recurrence rates post-treatment. These limitations have accelerated the exploration of novel immunotherapeutic approaches, particularly those targeting the tumor immune microenvironment. A critical molecular target in OSCC is CD47, a glycoprotein overexpressed on tumor cells. CD47 interacts with signal regulatory protein α (SIRPα) on macrophages, transmitting a "don't eat me" signal and facilitating immune evasion. While CD47 blockade can disrupt this signal and stimulate macrophage-mediated tumor clearance, its efficacy is curtailed by two primary issues: inadequate pro-phagocytic (“eat me”) signaling and the extracellular matrix (ECM) barrier, which restricts macrophage infiltration.

This reference study specifically addresses whether combining photothermal therapy (PTT) with CD47 blockade can overcome these immunological and structural barriers in OSCC, thereby offering a more potent anti-tumor strategy.

Key Innovation from the Reference Study

The central innovation in this work lies in the dual-action synergy between PTT and CD47 blockade. Photothermal therapy, using near-infrared (NIR) dyes such as indocyanine green, induces localized heat in tumor tissues, triggering immunogenic cell death (ICD) and exposing calreticulin (CRT) on the cell surface—a crucial pro-phagocytic "eat me" signal. Simultaneously, PTT downregulates ECM components, dismantling physical barriers and enabling macrophage infiltration. When combined with CD47 blockade, which removes the inhibitory “don’t eat me” signal, this strategy delivers a robust two-pronged attack: it both signals macrophages to engage and grants them physical access to tumor cells. This approach addresses the major mechanistic and translational bottlenecks previously limiting the effectiveness of immunotherapies targeting CD47 in solid tumors.

Methods and Experimental Design Insights

The study utilized both in vitro and in vivo models to dissect the mechanistic interplay between PTT and CD47 inhibition:

• Phagocytosis Assays: Flow cytometric analysis quantified macrophage uptake of tumor cells under various treatment conditions.
• Tumor Growth Inhibition: Murine OSCC models were monitored for tumor volume following combined or single-agent therapy.
• Immunogenic Cell Death Markers: Release of ATP, HMGB1, and membrane exposure of CRT were measured to confirm induction of ICD by PTT.
• Confocal Microscopy: Co-localization studies visualized the interaction between CRT-expressing tumor cells and infiltrating macrophages.
• ECM Component Analysis: Expression levels of ECM proteins were assessed at both mRNA and protein levels.
• Immunofluorescence: Quantified macrophage infiltration into the tumor microenvironment post-treatment.

Importantly, the study employed indocyanine green as the NIR-absorbing agent for PTT, leveraging its established safety and rapid vascular confinement, which have been well-documented in both diagnostic and therapeutic contexts (internal review).

Core Findings and Why They Matter

The principal outcomes from the reference study are:

• Enhanced Phagocytosis: The combination of PTT and CD47 blockade significantly increased macrophage uptake of OSCC cells in vitro, surpassing either modality alone.
• Robust Tumor Growth Inhibition: In vivo, the dual treatment produced marked tumor regression, correlating with increased macrophage infiltration and activity.
• Immunogenic Cell Death Induction: PTT triggered the release of ATP and HMGB1, and, most critically, membrane exposure of calreticulin, providing the necessary “eat me” signal for macrophages.
• ECM Remodeling: PTT downregulated key ECM components, facilitating the “come near me” process by making tumor nests physically accessible to immune cells.
• Mechanistic Confirmation: Confocal imaging validated co-localization of CRT-expressing tumor cells with infiltrating macrophages, supporting the functional relevance of CRT exposure.

These findings collectively demonstrate that PTT can overcome two core obstacles to CD47-targeted immunotherapy: insufficient pro-phagocytic signaling and the physical ECM barrier. The dual strategy activates both molecular and spatial cues necessary for robust macrophage-mediated clearance of tumor cells.

Comparison with Existing Internal Articles

Several internal reviews provide complementary perspectives on the utility of Cardiogreen (indocyanine green) in both diagnostic and therapeutic workflows:

• Mechanisms and Applications: This article highlights the pharmacokinetics and safety profile of Cardiogreen for cardiac output measurement and vascular imaging. The current study extends these principles to immunogenic phototherapy, underscoring the dye’s translational potential beyond diagnostics.
• Precision, Immunogenicity, and Next-Gen Phototherapy: Here, the focus is on Cardiogreen’s role in immunogenic cell death and transcriptome-level apoptosis induction—concepts directly paralleled in the reference study, which links CRT exposure and ICD to improved immunotherapy efficacy.
• Applied Protocols & Innovations: This workflow-oriented piece provides validated guidance on experimental conditions and highlights the operational advantages of high-purity Cardiogreen, echoing the reproducibility required in the reference study’s photothermal protocols.

Together, these resources confirm the versatility of Cardiogreen in both established and emerging biomedical applications, including its synergy with immunotherapeutic strategies in oncology.

Limitations and Transferability

While the reference study offers robust mechanistic insights, several caveats merit attention:

• Preclinical Focus: Findings are primarily derived from murine models and in vitro assays. The translatability to human OSCC remains to be demonstrated in clinical trials.
• Dye-Specific Effects: The immunomodulatory impact of indocyanine green in the context of PTT may vary with formulation, dosing, and irradiation parameters. Extrapolation to other photosensitizers or cancer types should be approached with caution.
• Macrophage Heterogeneity: Tumor-associated macrophages in OSCC exhibit phenotypic diversity; the net effect of combined therapy may differ in tumors with varying immune microenvironments.
• ECM Complexity: The extent and nature of ECM remodeling by PTT are influenced by tumor stage and stromal composition, potentially impacting treatment reproducibility.

Nevertheless, the central mechanism—PTT-induced CRT exposure and ECM remodeling to potentiate CD47 blockade—provides a strong foundation for future translational studies targeting solid tumors with immune-evasive features.

Protocol Parameters

• Cardiogreen (Indocyanine Green) administration: Typical protocols involve intravenous injection of 1000 μg/mL Cardiogreen, followed by a 5-minute incubation before irradiation.
• Photothermal therapy exposure: Apply near-infrared diode laser (e.g., 790 nm) for 60 seconds to induce localized hyperthermia and immunogenic cell death.
• Macrophage co-culture: For in vitro ICD and phagocytosis assays, co-incubate treated tumor cells with bone marrow-derived macrophages and assess phagocytic uptake by flow cytometry.
• Detection of immunogenic cell death: Quantify ATP and HMGB1 release in supernatants; confirm CRT membrane exposure using immunofluorescence or confocal microscopy.
• ECM analysis: Evaluate ECM gene and protein expression by qPCR and western blot, respectively, post-PTT treatment.

For more detailed implementation, see practical guidance in the applied protocols internal article.

Research Support Resources

Researchers seeking to reproduce or extend these findings can employ Cardiogreen (Indocyanine Green) (SKU B8315) for photothermal and immunogenicity workflows. This nontoxic, high-purity tricarbocyanine dye is validated for applications in cardiac output measurement, liver blood flow assessment, ophthalmic angiography, and as a photosensitizer for photodynamic therapy, including apoptosis induction in preclinical models. APExBIO provides quality assurance through HPLC, MS, and NMR analyses, supporting rigorous experimental design without compromising reproducibility.